Clinigen buys remaining rights to Novartis cancer drugUK pharma Clinigen has bought the remaining rights to Novartis’ cancer drug Proleukin, in a deal worth up Share XClinigen buys remaining rights to Novartis cancer drughttps://pharmaphorum.com/news/clinigen-buys-remaining-rights-to-novartis-cancer-drug/
Novartis spent $15bn on M&A last year, with more to comeThe comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last Share XNovartis spent $15bn on M&A last year, with more to comehttps://pharmaphorum.com/news/novartis-spent-15bn-on-ma-last-year-with-more-to-come/
2018 breaks records for digital health investment: reportGlobal funding in digital health companies reached new highs last year as $9.5 billion was raised in 698 Share X2018 breaks records for digital health investment: reporthttps://pharmaphorum.com/news/2018-breaks-records-for-digital-health-investment-report/
Takeda mulling sale of emerging market drugs – reportTakeda could be considering selling some emerging-market drugs in a bid to cut debts following its merger with Share XTakeda mulling sale of emerging market drugs – reporthttps://pharmaphorum.com/news/takeda-could-sell-emerging-market-drugs/
Lilly’s CEO looks to M&A, but not for CAR-T or gene therapiesEli Lilly’s CEO David Ricks could sign more deals to strengthen its pipeline of cancer drugs, but is Share XLilly’s CEO looks to M&A, but not for CAR-T or gene therapieshttps://pharmaphorum.com/news/lillys-ceo-looks-to-ma-but-not-for-car-t-or-gene-therapies/
EUSA Pharma buys rights to Janssen rare disease drugUK-based EUSA Pharma has bought worldwide rights to Janssen’s rare diseases drug Sylvant (siltuximab) for $115 million. EUSA Share XEUSA Pharma buys rights to Janssen rare disease drughttps://pharmaphorum.com/news/eusa-pharma-buys-rights-to-janssen-rare-disease-drug/
Takeda’s Shire takeover could herald new era of pharma M&ATakeda has officially taken over Shire in a deal that could re-establish the trend for mega mergers in Share XTakeda’s Shire takeover could herald new era of pharma M&Ahttps://pharmaphorum.com/news/takedas-shire-takeover-could-herald-new-era-of-pharma-ma/
2018 set benchmark for digital health investment – reportLast year was the biggest ever for digital health investment, according to a report that has been tracking Share X2018 set benchmark for digital health investment – reporthttps://pharmaphorum.com/news/2018-set-benchmark-for-digital-health-investment-report/
Lilly further boosts cancer pipeline with $8bn Loxo acquisitionIn the second big M&A deal of the year following BMS’s acquisition of Celgene, Eli Lilly has announced Share XLilly further boosts cancer pipeline with $8bn Loxo acquisitionhttps://pharmaphorum.com/news/lilly-further-boosts-cancer-pipeline-with-8bn-loxo-acquisition/
